Presently, several drugs targeting SCD1 in tumor treatment, such as CAY‐10566 and MF‐438, have only been tested in preclinical trials, primarily owing to weight loss and severe adverse effects on the skin and eyes [227]. The gene discussed is SCD; the disease is neoplasm.